Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04515784 · ClinicalTrials.gov registry record · NA

Safety Aid Reduction Treatment for PTSD Among Veterans

A NA study, sponsored by VA Office of Research and Development.

Completed
Registry status
NA
Development phase
45
Enrollment target

NCT04515784: Completed NA study, sponsored by VA Office of Research and Development.

NCT04515784 is a NA study that has completed, run by VA Office of Research and Development. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT04515784, a NA study, has completed, sponsored by VA Office of Research and Development.

COMPLETED
Registry status
NA
Development phase
45 participants
Enrollment target

Study Summary

The purpose of this project is to examine the acceptability, feasibility, and utility of a safety aid reduction treatment (START) among Veterans with posttraumatic stress disorder (PTSD). It is hypothesized that START will be acceptable, feasible, and will lead to reductions in PTSD symptom severity immediately and over time.

Primary Outcome

The CAPS-5 is a 30-item clinician-administered interview designed to assess current (i.e., past month) and lifetime PTSD diagnostic status. In addition to assessing the 20 DSM-5 PTSD symptoms, the CAPS-5 contains questions regarding the onset and duration of symptoms, associated impairment in various life domains, and specifications for the dissociative subtype. The past month CAPS-5 will be administered at baseline and one-month follow-up to assess changes in PTSD diagnostic status.

Interventions

  • BEHAVIORAL Safety Aid Reduction Treatment for PTSD

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2024-09-23
Est. Completion 2025-09-30
Phase NA
VA Office of Research and Development

1,668 total trials

What the finished NCT04515784 record still lists

NCT04515784 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 1 intervention - of which Safety Aid Reduction Treatment for PTSD is the first listed.

NCT04515784 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04515784 about?

NCT04515784 is a clinical study titled "Safety Aid Reduction Treatment for PTSD Among Veterans". The purpose of this project is to examine the acceptability, feasibility, and utility of a safety aid reduction treatment (START) among Veterans with posttraumatic stress disorder (PTSD). It is hypothesized that START will be acceptable, feasible, and will lead to reductions in PTSD symptom severity...

What is the current status of trial NCT04515784?

This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2024-09-23. Estimated completion is 2025-09-30.

What interventions are being tested in trial NCT04515784?

The interventions under investigation include: Safety Aid Reduction Treatment for PTSD (BEHAVIORAL).

Who is sponsoring clinical trial NCT04515784?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04515784's enrollment target sits among peer trials

45 1411th of 2000 higher than 578 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04515784, the US trial registry maintained by the National Library of Medicine. NCT04515784 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.